Bicara Therapeutics (NASDAQ:BCAX) used its inaugural quarterly earnings call to highlight recent regulatory momentum, updated clinical data for its lead program ficerafusp alfa, and a strengthened balance sheet following an oversubscribed public offering.
Company overview and recent milestones
Chief Executive Officer Claire Mazumdar described Bicara as a clinical-stage biotech focused on bifunctional antibodies for targeted tumor modulation, with its lead asset ficerafusp alfa (“ficera”) designed to combine EGFR targeting with a TGF-beta ligand trap. Mazumdar said the approach is intended to localize to tumors while modulating the tumor microenvironment to reduce fibrosis and immunosuppression and to address TGF-beta-driven resistance mechanisms.
- Breakthrough Therapy Designation from the FDA for ficerafusp alfa in combination with pembrolizumab for first-line treatment of metastatic or unresectable HPV-negative recurrent head and neck squamous cell carcinoma (HNSCC).
- Presentation of additional Phase 1b datasets across “clinically active doses,” which she said supported consistency in overall response rates and helped de-risk the overall response rate endpoint planned for an interim analysis.
- Selection of 1,500 mg as the optimal biological dose and progression into the Phase III portion of the pivotal FORTIFY-HN01 study, with an interim analysis expected “in the middle of next year,” according to Mazumdar.
- A plan to pursue a loading and every-three-week maintenance dosing strategy, which Mazumdar characterized as a commercial decision informed by updated clinical, translational, and pharmacokinetic data.
- Completion of an oversubscribed public offering to support accelerated investment in early commercial and medical infrastructure.
Clinical update: Phase 1b experience and dosing strategy
President and Chief Operating Officer Ryan Cohlhepp said Bicara has reported clinical experience in “approximately 90 patients” across three Phase 1b cohorts evaluating ficerafusp alfa plus pembrolizumab in frontline recurrent/metastatic HPV-negative HNSCC.
Cohlhepp said the 1,500 mg weekly dataset is the most mature, with two years of follow-up, and showed a median duration of response of 21.7 months and median overall survival of 21.3 months. He described this as “nearly tripling the median overall survival observed with the standard of care pembrolizumab in HPV-negative patients,” as characterized on the call.
He also pointed to:
- Data from a 750 mg weekly cohort presented at ESMO Asia in December 2025, which he said helped inform selection of 1,500 mg weekly as the optimal biological dose for the pivotal trial.
- Data from a 2,000 mg every-two-week cohort presented at the Multidisciplinary Head and Neck Cancers Symposium, which the company said supported developing a less frequent loading and maintenance dosing option.
According to Cohlhepp, tumor shrinkage was observed across all doses and “trends deeper with higher exposure.” He said translational data showed consistent TGF-beta inhibition across doses, with the strongest inhibition seen with 1,500 mg weekly and the less frequent 2,000 mg regimen. Cohlhepp argued that TGF-beta-driven depth of response is a differentiator versus EGFR-directed therapies that do not target TGF-beta.
Responding to an analyst question about the rationale for a loading phase followed by every-three-week maintenance, Cohlhepp said exposure-response modeling across the 750 mg weekly, 1,500 mg weekly, and 2,000 mg every-two-week datasets supported the approach. He added that responses in the Phase 1b program were rapid, with responses occurring at about 1.4 months, and said most patients achieved response within 12 weeks and reached maximal depth of response by that timepoint—factors he said support the ability to extend the dosing interval after an initial weekly phase.
FORTIFY-HN01 enrollment and interim analysis approach
Management fielded several questions on enrollment progress for FORTIFY-HN01 and the company’s plans for a parallel study to support an alternative regimen.
Chief Development Officer Tanya Green said that, as publicly available, Bicara currently has 129 active sites globally and remains focused on achieving “substantial enrollment by the end of this year,” which she said would keep the company on track for an interim analysis by mid-2027. (Cohlhepp also said the geographic distribution was expected to be similar to historical trials such as KEYNOTE-048.)
On competitive overlap, Green said there are some overlapping sites with other studies, but the company has seen “great momentum” at its sites and does not view overlap as a key consideration.
Regarding the planned study for less frequent dosing, the company said it is seeking regulatory alignment before providing more details. On the call, management estimated the study size could be “anywhere between 150-200 patients,” while emphasizing that plans may evolve following FDA feedback.
Management also addressed the interim analysis and blinding. In response to a question about unblinding, the company said the trial is fully double-blinded and that management will not be unblinded. Instead, at the time of the pre-specified statistical analysis, an independent committee will evaluate overall response rate, durability, and “qualitative overall survival,” while the trial continues toward an overall survival endpoint.
On regulatory strategy, management said it believes it is “on a path” in the U.S. to potential accelerated approval based on a response-rate endpoint at interim analysis, with durability of response and qualitative overall survival also assessed, while noting that ex-U.S. approvals are expected to require overall survival for full approval.
Other pipeline: colorectal cancer signal-seeking cohorts
Bicara also discussed an upcoming colorectal cancer (CRC) update expected in the second half of the year. Cohlhepp said the number of patients included may vary based on enrollment, but the company generally aims to present datasets of “no less than 20 patients per cohort.” He said Bicara is exploring signal-seeking cohorts in third-line CRC, including a monotherapy cohort and a cohort combining ficerafusp alfa with pembrolizumab at 1,500 mg weekly.
Asked about inclusion criteria, Cohlhepp said the CRC enrollment criteria allows liver metastases, and he referenced previously presented anal canal data that he said showed the company’s ability to resolve liver metastases in that population.
Financial update: higher investment outlook and extended runway
Chief Financial Officer Ivan Hyep said operating expenses increased in 2025 versus 2024, driven by clinical operations and development expenses, including increased manufacturing and process development costs tied to FORTIFY-HN01. He also cited higher personnel-related costs, including stock-based compensation, as the company expanded headcount primarily to support clinical operations and development.
Hyep said Bicara anticipates a further increase in operating expenses in 2026, driven by investment in clinical operations for the pivotal study as well as increased SG&A and headcount as the company builds early commercial and medical infrastructure for a potential launch.
On liquidity, Hyep said Bicara entered 2026 with $414.8 million in cash, cash equivalents, and marketable securities. He added that the company raised $161.8 million in net proceeds in the first quarter through an oversubscribed public offering and maintained runway guidance “into the first half of 2029.”
Hyep said the additional capital is intended to support a planned regulatory filing for ficerafusp alfa, fund a less frequent dosing schedule effort, expand medical and commercial infrastructure, support manufacturing needs for ongoing and anticipated development, and fund early signal-finding work for potential indication expansion, among other corporate purposes. Addressing why runway guidance was maintained despite the raise, Hyep said the company is using proceeds to “build up” investments—particularly alternative dosing and pre-launch activities—rather than simply extending runway.
About Bicara Therapeutics (NASDAQ:BCAX)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
